Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01427933 · ClinicalTrials.gov registry record · Phase 2
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
NCT01427933 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 141 participants.
The verdict
NCT01427933, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
Study Summary
This is a study to compare the antitumor activity of ramucirumab (IMC-1121B) and eribulin together versus eribulin alone, in participants with locally recurrent or metastatic breast cancer.
Interventions
- DRUG Eribulin
- BIOLOGICAL Ramucirumab (IMC-1121B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01427933
The ClinicalTrials.gov registry entry for NCT01427933 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eribulin is the first listed.
NCT01427933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01427933 about?
NCT01427933 is a clinical study titled "A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer". This is a study to compare the antitumor activity of ramucirumab (IMC-1121B) and eribulin together versus eribulin alone, in participants with locally recurrent or metastatic breast cancer.
What is the current status of trial NCT01427933?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2011-11. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01427933?
The interventions under investigation include: Eribulin (DRUG), Ramucirumab (IMC-1121B) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01427933?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.